Drug Approval | April 10, 2024
Shivalik Rasayan’s API facility gets 7 observations from USFDA
These observations are procedural in nature and will be responded within the stipulated time
These observations are procedural in nature and will be responded within the stipulated time
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
The observations are procedural in nature and will be responded to within the stipulated time
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
The Product is expected to be the first generic approval on the market
A game changing solution for the pharmaceutical industry
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Subscribe To Our Newsletter & Stay Updated
